A Surprising Benefit of mRNA Vaccines
New research suggests that COVID-19 vaccines may do more than protect people from the virus — they might also help some cancer patients fight their tumours. According to a study published in the journal Nature, patients with advanced lung or skin cancer who received Pfizer or Moderna vaccines within 100 days of starting immunotherapy lived significantly longer than those who did not.
Scientists from MD Anderson Cancer Center in Houston and the University of Florida led the study. They discovered that the mRNA technology used in these vaccines helps the immune system respond more effectively to cancer treatment. “The vaccine acts like a siren to activate immune cells throughout the body,” explained lead researcher Dr. Adam Grippin. “We’re sensitizing immune-resistant tumours to immune therapy.”
The finding was unrelated to COVID-19 infection itself. Instead, it was the vaccine’s messenger RNA (mRNA) — the molecule that instructs cells to make proteins — that boosted the immune system’s response. This discovery may open new possibilities for combining mRNA vaccines with cancer immunotherapy.
Promising Early Results for Patients
Researchers analyzed data from nearly 1,000 patients undergoing checkpoint inhibitor treatment, a type of immunotherapy that helps immune cells recognize and attack cancer cells. They found that lung cancer patients who had received mRNA COVID-19 vaccines were nearly twice as likely to survive three years after starting treatment compared to unvaccinated patients. For melanoma patients, survival was also significantly better among the vaccinated group.
Interestingly, other vaccines like the flu shot did not show the same effect, suggesting that the mRNA component plays a special role. While more research is needed, the team is already planning larger studies to see if combining mRNA vaccines with checkpoint inhibitors could become a standard cancer treatment.
Experts like Dr. Jeff Coller from Johns Hopkins University, who was not involved in the study, believe this research gives “a very good clue” that mRNA medicines could have even broader benefits for human health.
